Related Experiment Videos
Chronic beta 1-blockade and control of left ventricular hypertrophy in hypertension
Insights
Chronic beta-blocker therapy lowers blood pressure and reduces left ventricular hypertrophy (LVH) in hypertensive patients. However, it may not fully reverse existing LVH, highlighting the importance of early hypertension detection and treatment.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Essential hypertension is a significant risk factor for left ventricular hypertrophy (LVH).
- Electrocardiogram (ECG) indexes, such as the Sokolow-Lyon Index (SLI), are used to assess LVH.
- Beta-blocking agents are commonly prescribed for hypertension management.
Purpose of the Study:
- To evaluate the long-term effects of atenolol (a beta-blocker) on ECG-detected LVH in hypertensive patients.
- To assess the impact of beta-blocker therapy on blood pressure control and LVH regression.
Main Methods:
- A 5-year prospective study involving 71 hypertensive patients (mean age 47 years).
- Patients were categorized into treated with LVH, treated without LVH, and untreated with LVH groups.
- Sokolow-Lyon voltage criteria were used to diagnose and monitor ECG-detected LVH (ECGLVH).
Main Results:
- Beta-blocker therapy significantly reduced blood pressure (BP) in treated patients.
- In patients with ECGLVH, atenolol treatment improved the SLI but did not lead to complete regression in most cases (only 11.4% normalized).
- Untreated patients with ECGLVH showed a significant increase in SLI over the study period.
Conclusions:
- Beta-blocker therapy effectively reduces LVH in hypertensive patients by lowering BP, but complete regression of established hypertrophy is limited.
- Inadequate BP control can lead to the progression of LVH.
- Early detection and treatment of hypertension are crucial to prevent the development and progression of LVH.
Abstract:
The aim of this study is to evaluate the effects of chronic beta-blocking therapy (atenolol 100 mg/d) on ECG and ECG indexes of left ventricular hypertrophy (LVH) in hypertensive patients. Seventy one subjects with essential hypertension (mean age 47 y) were studied for 5 years. Sokolow-Lyon voltage criteria for ECGLVH (S wave in V1 plus R wave in V5 greater than or equal to 35 mm) were employed in: 38 treated patients with ECGLVH, 12 treated patients without ECGLVH and 21 untreated patients with ECGLVH. Beta-blocking therapy significantly reduced blood pressure (BP) in the treated patients. In the patients with ECGLVH, treatment significantly improved Sokolow-Lyon Index (SLI) reducing it from 55.04 +/- 16.2 mm to 47.6 +/- 15.04 mm (p less than 0.05) but only 11.4% of the treated patients returned within the normality range (SLI less than 35 mm). No significant change was present in the treated patients without ECGLVH. On the contrary, the group of untreated patients showed an increase in SLI from 45.19 +/- 7.08 mm to 50.52 +/- 11.09 mm (p less than 0.05) and no change in hypertension levels. We conclude, therefore, that: ineffective BP control allows progression of LVH; BP reduction by beta-blocking drugs reduces LVH but does not produce complete regression of the hypertrophy, if not in the early stages; if no LVH is present, BP control by these drugs prevents LVH. We emphasize the importance of early detection and treatment of hypertension.